Bill & Melinda Gates Foundation

Established in 2000 by Bill and Melinda Gates, this foundation is dedicated to enhancing healthcare, reducing extreme poverty globally, and expanding educational opportunities. It operates regionally with offices in Seattle, Washington D.C., New Delhi, Beijing, and London.

Harish Iyer Ph.D

Deputy Director, Digital and Health Innovation

Chris Karp

Director, Global Health Discovery and Translational Sciences

Keith Klugman

Director

Trevor Mundel

President, Global Health

Rob Nabors

Director, North America

Vipula Shukla Ph.D

Senior Program Officer, Agriculture R&D

Lynda Stuart

Deputy Director

Mark Suzman

President, Global Policy and Advocacy

Chris Wilson

Director

348 past transactions

Likarda

Grant in 2025
Likarda is a biotechnology company focused on cell therapies and enabling technologies that improve delivery and function. Its Core-Shell Spherification platform encapsulates therapeutic cells in hydrogel microcapsules using biocompatible materials such as hyaluronic acid, PEG and PVA, enabling customizable formulations tailored to each therapy. The platform supports two delivery approaches: injectable, slow-release formulations that localize cells for enhanced efficacy, and immunoprotective coatings that protect cells during injection or transplantation for longer-term treatment. In addition to cell therapies, the hydrogel coating method can formulate and deliver peptides, antibodies and exosomes while preserving their activity at the target site. Likarda aims to advance therapies for diabetes and osteoarthritis, including islet-like cell delivery for diabetes and encapsulated stem cells for joint degeneration, through preclinical work in animal models.

Synvect

Seed Round in 2025
Synvect is a biotechnology company that develops innovative solutions to control mosquito populations, with a focus on eliminating disease-carrying mosquitoes. The company's core technology involves using clustered regularly interspaced short palindromic repeats (CRISPR) gene editing to sterilize mosquito eggs, thereby preventing the breeding of disease-transmitting mosquitoes. Synvect's services aim to suppress harmful mosquito populations, enabling researchers to focus on eradicating mosquito-borne illnesses through affordable and user-friendly biological methods.

Leinco Technologies

Grant in 2025
Leinco Technologies is a company that specializes in the development of high-purity monoclonal antibodies, proteins, and various reagents specifically for the diagnostic and biopharmaceutical industries. They provide a range of services, including in vitro antibody and protein production, antibody conjugations, and cell banking. Leinco Technologies focuses on augmenting the early discovery process in life science research and diagnostics, as well as contributing to the innovative development of protein therapeutics. Their expertise in optimizing and adapting products enables clients to effectively meet their research and development needs.

SeamlessHR

Series A in 2025
SeamlessHR Limited is a human resource technology software company based in Lagos, Nigeria, founded in 2013. It specializes in creating enterprise-grade, cloud-based HR solutions designed to automate and optimize the entire HR process for medium to large-sized organizations. The company's comprehensive product suite includes a Recruitment Management System, HR Information System (HRIS), Performance and Competency Management, Payroll Management, Leave Management, and Learning Management System, among other modules. These tools facilitate various HR functions such as recruitment, training, payroll processing, performance evaluation, and analytics, enabling businesses to streamline their human resource operations from recruitment to retirement. Additionally, SeamlessHR provides embedded finance solutions that enhance financial security for both employers and employees.

The Independent

Grant in 2025
The Independent is a global newsbrand dedicated to delivering independent news, commentary, and analysis. It operates a weekly newspaper that covers a wide range of topics, including sports, business, fashion, lifestyle, real estate, entertainment, and local news. In addition to its print publication, The Independent offers digital news articles and investigative reporting through its website and mobile applications. The company aims to keep its readers informed about current affairs and significant global incidents, positioning itself as a source for those seeking diverse perspectives and insights.

ReciBioPharm

Grant in 2025
ReciBioPharm operates as a biologics company. ReciBioPharm is a division of Recipharm.

Micron Biomedical

Grant in 2025
Founded in 2014, Micron Biomedical is a clinical-stage biopharmaceutical company based in Atlanta, Georgia. It specializes in developing microneedle patches for vaccines, aiming to enhance protective effects and patient compliance while simplifying administration.

Aptitude Medical Systems

Grant in 2025
Aptitude Medical Systems is a biotechnology research company specializing in molecular recognition technology that utilizes aptamers to address the limitations of traditional antibodies. By developing highly stable and resistant aptamers, the company offers solutions that bind with high affinity and specificity to challenging targets, even discriminating between targets that differ by a single functional group. This innovation enables a range of applications across life sciences, diagnostics, and therapeutics, facilitating the creation of advanced products tailored to meet the stringent demands of molecular recognition. Through its partnerships, Aptitude aims to advance the capabilities of molecular diagnostics and therapeutic interventions.

Tessera Therapeutics

Venture Round in 2024
Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

Avanti Finance

Series B in 2024
Avanti Finance develops digital financial inclusion platforms. It offers loan products and capital for third parties, aiming to provide accessible financing solutions to those underserved by traditional banking systems.

WindBorne Systems

Venture Round in 2024
WindBorne Systems, founded in 2019 and based in Stanford, California, specializes in developing and operating a network of long-duration smart weather balloons. These high-altitude balloons are equipped with sensors to gather precise atmospheric measurements from various layers of the atmosphere. The company collects valuable data for weather forecasting, climate research, and environmental monitoring, which is then distributed to government and private weather services. By providing high-resolution atmospheric data, WindBorne Systems enhances the accuracy of weather predictions, aiding in the mitigation of severe weather events and contributing to better adaptation strategies for climate change.

Vitrivax

Grant in 2024
VitriVax is a biotechnology startup based in Boulder, Colorado, dedicated to advancing vaccine formulation through its innovative technology platform. The company has developed proprietary atomic layering thermostable antigen and adjuvant (ALTA) technology, which aims to enhance the effectiveness, affordability, and accessibility of both human and animal vaccines worldwide. This technology allows for the creation of thermostable, single-shot vaccines that can maintain or improve immune responses, enabling the incorporation of prime and booster doses in a single administration. With significant financial backing from various organizations, including the Bill and Melinda Gates Foundation, VitriVax addresses critical barriers to global vaccination, striving to improve public health outcomes.

Magma Math

Grant in 2024
Magma Math is an e-learning math platform for K–12 classrooms that helps improve teaching practises and learning for students.

Biosurfaces

Grant in 2024
BioSurfaces is a developer of medical devices specializing in tissue engineering and personal care products. The company leverages advanced electrospinning technology to produce nanofibrous materials that facilitate controlled drug delivery and enhance healing at the implant site. By utilizing a room-temperature electrospinning process, BioSurfaces enables the integration of drug loading within each fiber, creating a reservoir for sustained drug release. This innovative approach allows for the creation of devices and coatings as thin as 10 micrometers, making it possible to treat diseases directly at the site of implantation. The company aims to provide next-generation solutions for the medical and personal care markets, focusing on improving patient outcomes through effective disease treatment and tissue regeneration.

Insud Pharma

Grant in 2024
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health.

Dyadic International

Grant in 2024
Dyadic International is a global biotechnology company headquartered in Jupiter, Florida, with its research and development center in the Netherlands. The company uses its patented and proprietary technologies to conduct research, development, and commercial activities for the discovery, development, manufacture, and sale of enzymes and other proteins for diverse industries including bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes.

Freya Biosciences

Series A in 2024
Freya Biosciences is a clinical-stage company specializing in women's health. It develops microbial immunotherapies, focusing on unmet needs across various indications.

Canyon GBS

Grant in 2024
Based in the vibrant Phoenix Metro Area and supported by a global team, Canyon GBS® is a pioneering tech company crafting impactful solutions powered by AI. With a diverse range of offerings tailored for sectors such as higher education, public sector government agencies, non-profits, and small businesses, Canyon GBS® is dedicated to enhancing operational efficiency. Our mission is to equip organizations with powerful yet accessible AI-powered technology to better serve their constituents. Through our relentless pursuit of innovation and customer-centric approach, Canyon GBS® strives to be a trusted partner in navigating today's digital landscape.

La Ruche Health

Grant in 2024
La Ruche Health connects patients with virtual and at-home healthcare services via its AI-driven platform. It offers advice through text, voice, and images, facilitating easy booking of medical appointments and lab tests via iOS, Android, and WhatsApp.

PopVax

Grant in 2024
PopVax is a biotechnology company that developing novel mRNA vaccines and therapeutics using computational protein design.

ApiJect

Grant in 2024
ApiJect is a medical technology company that provides a platform for creating scalable prefilled injectors and performing fill-finish of injectable drugs. The platform can operate on its own Blow-Fill-Seal lines or with manufacturing partners, enabling broad adoption of prefilled, single-dose injections. The technology replaces glass, aluminum, rubber, and silicone with medical-grade plastic resin, simplifying the supply chain and reducing environmental impact. By enabling pharma and biotech companies to produce affordable medicines and vaccines, ApiJect helps deliver safe, widely accessible injectable therapies to more patients.

Stellapps

Series C in 2024
Stellapps develops dairy management software that uses a full-stack IoT platform, analytics and AI to improve dairy supply chain performance. Its technology integrates IoT, big data, cloud and mobility to enhance milk production, procurement, cold chain management and farmer payments, while providing end-to-end traceability across the dairy ecosystem. The platform supports collaborations with financial and insurance institutions, veterinary services and cattle nutrition providers, and aims to create value for dairy farms, cooperatives and smallholder farmers by boosting productivity, quality and profitability with reduced effort.

AN2 Therapeutics

Grant in 2024
AN2 Therapeutics is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative medicines targeting infectious diseases. Established in 2017, the company focuses on advancing a clinical-stage antibacterial compound and has a strategic partnership with Brii Biosciences.

CanSino Biologics

Grant in 2024
CanSino Biologics focuses on the R&D, manufacturing, and commercialization of vaccine products for human use. These vaccine products include pneumococcal polysaccharide and conjugate vaccines, and a DTcP-based combo, and other items. It is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine.

Imperial College London

Grant in 2024
Imperial College London is renowned globally for its science, technology, engineering, medicine, and business programs. It fosters innovation and entrepreneurship, offering resources to students and promoting idea exchange across its campuses and international network.

Chemify

Grant in 2024
Chemify specializes in developing a chemical digitization platform designed to facilitate drug and materials discovery as well as chemical synthesis. The company's innovative approach involves using automated synthetic hardware combined with digital XDL code to convert code into molecules on demand. This system is modular, universal, scalable, and teachable, making it highly versatile for various applications in chemical and material research. Chemify's software includes a unique chemical programming language and natural language recognition capabilities that translate synthetic procedures efficiently. Additionally, the platform features a comprehensive ontology that provides detailed insights into reaction conditions and flags potential issues, offering scientists real-time telemetry of reactions.

Radiant Biotherapeutics

Series A in 2024
Radiant Biotherapeutics is a pioneering company developing a modular platform for creating multi-valent and multi-specific antibodies. This innovative approach aims to deliver transformative therapies for challenging diseases like cancer, autoimmune disorders, and infections by harnessing the power of avidity and multi-specificity.

Eyam Vaccines and Immunotherapeutics

Grant in 2024
Eyam Vaccines and Immunotherapeutics is a life science and medical research company focused on the development of vaccines to combat infectious diseases. The company specializes in researching vaccines that target the spike glycoprotein, which is crucial for generating neutralizing antibodies against pathogens such as the novel coronavirus. Eyam employs a self-amplifying vaccine platform that enables the design of low-dose vaccines with advanced targeting capabilities, ensuring comprehensive protection, including against emerging variants. Through its innovative approach, the company aims to address pressing healthcare challenges and enhance public health outcomes.

Field

Grant in 2024
Field develops pharmaceutical supply-chain technology that digitizes, modernizes, strengthens, and sustains healthcare supply chains, enabling easy access to medicines. The platform is designed to be easy to use, scalable, and effective for governments and businesses delivering healthcare worldwide, supporting improvements in how medicines reach communities and helping ensure healthcare for millions.

Upsolve

Grant in 2024
Upsolve is a nonprofit organization based in New York City that assists low-income Americans in navigating the bankruptcy process. Founded in June 2016 by Jonathan Petts and Rohan Pavuluri, Upsolve offers a free online tool that guides users through a series of questions to generate the necessary Chapter 7 bankruptcy forms. Following this, the organization's lawyers review the completed forms to ensure accuracy and compliance. By automating the bankruptcy filing process, Upsolve aims to provide essential financial guidance and support to those facing sudden financial hardships, helping them achieve a fresh start.

Propel

Grant in 2024
Propel, Inc. is a software development company based in Brooklyn, New York, established in 2014. The company focuses on creating mobile applications aimed at improving the financial health of low-income Americans. Its primary product, Providers, is a free app designed for EBT cardholders, enabling them to manage their government benefits, such as SNAP and rental assistance. The app also helps users track their finances, save on essential purchases, and earn cash through various incentives. Propel's mission is to empower individuals by providing tools that facilitate better budgeting and financial management.

Legume Technology

Grant in 2024
Legume Technology is a producer of organic, contaminant-free, biostimulant products that are proven to increase yield. They provide services such as physicochemical improvement of pellets, compatibility testing, coating machinery, private labelling, marketing support, registration support from legume technology, pre-treatment inoculant training, application strategy and techniques. Their products like liquifix, liquifix 120, legumefix, molyfix, rootfix, extensive,and mycofix. They provide support for crops such as soya, peas, lupin, lucerne, wheat, chickpeas, clover, corn, and sunflower.

Immorna

Grant in 2024
Immorna is a biotechnology company focused on the development of RNA-based therapeutics and vaccines. The company employs various RNA platforms, including conventional, self-replicating, and circular RNA, to create innovative treatment solutions. Immorna has established a comprehensive management console that supports RNA synthesis, purification, and analytical testing, which is designed for both clinical and commercial applications. With advanced screening tools, the company has developed a range of RNA delivery vehicles, including polymers and lipid nanoparticles that utilize proprietary ionizable cationic lipids. This portfolio positions Immorna to effectively address a variety of medical needs through its cutting-edge RNA technology.

Noze

Venture Round in 2024
Noze specializes in digital odor perception technology, aiming to replicate the human sense of smell digitally. Utilizing advanced machine learning and an innovative sensor based on NASA technology, Noze detects and identifies odors with precision. Their primary goal is to improve patient outcomes by enabling real-time disease detection through breath-based biomarkers at any point-of-care.

Schrödinger

Grant in 2024
Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.

RiseKit

Grant in 2024
RiseKit, Inc. is a software company based in Chicago, Illinois, founded in 2016. It focuses on connecting entry to mid-level job seekers, particularly from underserved communities, with employment opportunities, training programs, and supportive services. By leveraging its platform, RiseKit aims to eliminate barriers to employment based on geographic and socioeconomic factors. The company's solutions serve nonprofits, employers, government entities, and community organizations, facilitating efficient connections between job candidates and available resources. RiseKit's mission is to ensure that all individuals, regardless of their background, have access to meaningful career pathways and that organizations can effectively measure their impact on the communities they serve.

SNIPR Biome

Grant in 2024
SNIPR Biome is a biotechnology company developing CRISPR-based therapies for treating microbial diseases. Founded in 2017 and headquartered in Copenhagen, Denmark, the company leverages CRISPR technology to selectively eliminate harmful bacteria by targeting their specific DNA sequences.

ETHRIS

Venture Round in 2024
Ethris GmbH is a biotechnology company based in Planegg, Germany, specializing in the development of innovative therapeutic solutions for diseases with unmet medical needs. The company has a focus on transcript therapeutics, particularly through its SNIM RNA platform, which offers a novel approach to treating various conditions by enabling the production of therapeutic proteins within the patient’s body. This platform presents an alternative to traditional recombinant protein and gene therapies, addressing a range of diseases, including rare and genetically predetermined conditions. Ethris also develops Magnetovax, a personalized tumor vaccine platform that utilizes magnetic fields for localized activation in tumors. The company has established strategic research collaborations with major pharmaceutical firms, enhancing its capabilities in regenerative medicine and therapeutic development. Founded in 2009, Ethris continues to advance its technologies to meet diverse medical needs.

Alan Turing Institute

Grant in 2024
The Alan Turing Institute is the national institute for data science. The Institute is named in honour of Alan Turing (23 June 1912 – 7 June 1954), whose pioneering work in theoretical and applied mathematics, engineering and computing are considered to be the key disciplines comprising the emerging field of data science.

Ben-Gurion University of the Negev

Grant in 2024
Ben-Gurion University of the Negev is one of Israel’s leading research universities and among the world leaders in many fields. It has around 20,000 students and 4,000 faculty members in the Faculties of Engineering Sciences; Health Sciences; Natural Sciences; the Pinchas Sapir Faculty of Humanities and Social Sciences; the Guilford Glazer Faculty of Business and Management; the Joyce and Irving Goldman School of Medicine; the Kreitman School of Advanced Graduate Studies; and the Albert Katz International School for Desert Studies. More than 100,000 alumni play important roles in all areas of research and development, industry, health care, the economy, society, culture and education in Israel. The University has three main campuses: The Marcus Family Campus in Beer-Sheva; the research campus at Sede Boqer and the Eilat Campus, and is home to national and multi-disciplinary research institutes: the National Institute for Biotechnology in the Negev; the National Institute of Solar Energy; the Ilse Katz Institute for Nanoscale Science and Technology; the Jacob Blaustein Institutes for Desert Research; the Ben-Gurion Research Institute for the Study of Israel & Zionism, and Heksherim - The Research Institute for Jewish and Israeli Literature and Culture.

Shomvob

Grant in 2024
Shomvob is an integrated fintech and HR-tech platform dedicated to empowering Bangladesh's rising frontline workforce. It facilitates job opportunities by helping users build digital professional identities, connect with networks, and access suitable jobs based on skills and qualifications. Additionally, it offers payroll financing as part of its financial inclusion initiatives.

Nanite

Grant in 2024
Nanite is a biotechnology company focused on non-viral gene delivery through the development of programmable polymer nanoparticles. Utilizing an artificial intelligence-driven platform, Nanite integrates advanced high-throughput experimental and computational techniques to create tailored delivery vehicles capable of transporting a diverse array of genetic materials with specific targeting capabilities. This innovative approach aims to assist scientists in functional chemistry by providing therapeutically relevant solutions for gene delivery, enhancing the potential for various medical applications and indications.

Surf Bio

Grant in 2024
Surf Bio is a preclinical biopharmaceutical company focused on developing innovative therapeutic solutions through its next-generation surfactant technology. This novel biotechnology platform aims to enhance drug effectiveness across various therapeutic areas, including diabetes, oncology, infectious diseases, and gene therapy. By utilizing this advanced technology, Surf Bio seeks to provide healthcare organizations worldwide with access to improved drugs that can better address the needs of patients suffering from critical diseases.

Owlstone Medical

Grant in 2024
Owlstone Medical develops and commercializes breathalyzers for clinical diagnostics and precision medicine. Its products detect volatile organic compounds in breath samples to diagnose diseases like lung cancer, asthma, and tuberculosis. The company has strategic collaborations with pharmaceutical companies and is based in Cambridge, UK.

Owlstone Medical

Venture Round in 2024
Owlstone Medical develops and commercializes breathalyzers for clinical diagnostics and precision medicine. Its products detect volatile organic compounds in breath samples to diagnose diseases like lung cancer, asthma, and tuberculosis. The company has strategic collaborations with pharmaceutical companies and is based in Cambridge, UK.

Sibel Health

Grant in 2024
Sibel Health, established in 2018 and headquartered in Evanston, Illinois, specializes in advanced monitoring solutions for healthcare. The company develops soft, flexible sensors that provide clinical-grade, wireless vital signs monitoring, including heart rate, respiratory rate, skin temperature, body position, and activities. These sensors are designed for use on patients and pregnant mothers, offering a comprehensive physiological monitoring platform with advanced analytics for both clinical care and research applications. Sibel Health's innovative digital health solutions are tailored for the pharmaceutical and clinical research sectors, enhancing healthcare delivery and patient outcomes.

Corner Therapeutics

Grant in 2024
Corner Therapeutics is a biotechnology company focused on immunotherapy research. It specializes in developing technologies that hyperactivate dendritic cells to induce robust and durable T-cell responses, aiming to provide lifelong immunity against various cancers and infectious diseases.

Pula Advisors

Series B in 2024
Pula GmbH is an insurance intermediary based in Mollis, Switzerland, specializing in agricultural insurance broking services. The company focuses on providing data-driven insurance solutions for small-scale farmers across six countries in Africa. By leveraging machine learning and analyzing weather patterns and farm losses, Pula helps farmers navigate climate risks and enhance their agricultural practices. Through the use of mobile technology, Pula empowers hundreds of thousands of smallholders to protect their crops and make informed financial decisions, ultimately enabling them to invest in their farms and improve their overall income.

Ginkgo Bioworks

Grant in 2024
Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Antibody Solutions

Grant in 2024
Antibody Solutions provides antigen design, polyclonal antibody generation, research and drug development for biopharmaceutical companies.

Detect-Ion

Grant in 2024
Detect-ION is a cutting-edge deep-tech startup that specializes in the development of sensors and systems for a variety of applications, with a focus on innovation and technological excellence.

Noze

Grant in 2024
Noze specializes in digital odor perception technology, aiming to replicate the human sense of smell digitally. Utilizing advanced machine learning and an innovative sensor based on NASA technology, Noze detects and identifies odors with precision. Their primary goal is to improve patient outcomes by enabling real-time disease detection through breath-based biomarkers at any point-of-care.

Phase Genomics

Grant in 2024
Phase Genomics is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing technology for ProxiMeta Hi-C genome assembly and metagenome deconvolution. Phase Genomics' platform aims to facilitate transformative discoveries in agriculture, human health, and industrial biology by providing scientists with highly accurate and detailed genomes and metagenomes. This enables researchers to make significant breakthroughs across various fields.

Food Fortification Initiative

Grant in 2024
Food Fortification Initiative is a non-profit organization that provides the fortification of industrially milled flour and rice globally.

PhaSER Biomedical

Grant in 2024
PhaSER Biomedical is Exploiting the 8HUM mouse, a unique mouse model with multiple utilities in drug discovery, and development.

C16 Biosciences

Grant in 2024
C16 Biosciences develops palm oil alternatives through microbial fermentation, producing high-performance lipids and oils to replace palm-derived ingredients in food, beauty, and consumer products. Using its fermentation platform, the company aims to deliver sustainable ingredients without conventional palm oil supply chains, reducing environmental impact. It markets Palmless, a platform for sustainable ingredients, and has introduced Torula oil, a bioactive oil with reported benefits for skin and hair health. Founded in 2017 and based in New York, C16 Biosciences serves food manufacturers, refiners, traders, and brands by providing reliable, environmentally friendly ingredients across beauty, personal care, home care, and food markets.

ProteinLogic

Grant in 2024
ProteinLogic’s ImmiPrint® technology impacts the emerging market for diagnostic, predictive, prognostic and other biomarker applications.

Picnic

Series E in 2024
Picnic is a rapidly expanding technology company that operates as an online supermarket, offering a modern home delivery system for fast-moving consumer goods. The company focuses on providing grocery shopping services at competitive prices without delivery costs. Through its platform, users can place orders for a wide range of products sourced from local bakers, greengrocers, and other suppliers. Picnic utilizes electric vehicles for deliveries, ensuring that customers receive their groceries conveniently at their doorsteps while promoting environmentally friendly practices.

Sail Biomedicines

Grant in 2024
Sail Biomedicines is a biotechnology company developing innovative medicines using circular RNA technology and programmable nanoparticles. Its platform, Endless RNA (eRNA), combined with unique, naturally-derived nanoparticles, enables the comprehensive programming of drugs, enhancing their potency and targeting capabilities. The company aims to transform patient care by leveraging artificial intelligence and advanced delivery systems to create first-in-class therapeutics.

Radiant Biotherapeutics

Grant in 2023
Radiant Biotherapeutics is a pioneering company developing a modular platform for creating multi-valent and multi-specific antibodies. This innovative approach aims to deliver transformative therapies for challenging diseases like cancer, autoimmune disorders, and infections by harnessing the power of avidity and multi-specificity.

Brightseed

Grant in 2023
Brightseed, Inc. is a pioneering biosciences company based in San Francisco, California, founded in 2017. It specializes in the discovery of bioactive compounds in plants that have beneficial effects on human health, particularly for chronic disease management. Utilizing its proprietary Forager platform, which incorporates artificial intelligence and machine learning, Brightseed accelerates the identification and validation of these naturally occurring compounds, transforming what was once a lengthy process into a matter of months. By mapping bioactives to specific health outcomes, Brightseed provides valuable insights and science-backed solutions to partners across the consumer health continuum. The company's innovative approach aims to illuminate the connections between nature and human health, ultimately improving quality of life and addressing health challenges through the exploration of previously uncharted plant compounds.

LTS Lohmann Therapie-Systeme AG

Grant in 2023
LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Evotec

Grant in 2023
Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Molecular Loop

Grant in 2023
Molecular Loop is a biotechnology company focused on DNA sequencing. The company offers a unique approach to sequencing through its Molecular Loop targeting technology, which eliminates the need for a separate library preparation process. This innovation allows for amplicons designed to overlap extensively across target strands, providing sequence data without the added complexity and costs associated with traditional shotgun library methods. Additionally, Molecular Loop provides custom assays based on user-provided content, along with expanded and customizable carrier screening panels and research panels for SARS-CoV-2. These offerings enable healthcare professionals and researchers to access efficient systems for production-scale targeted sequencing applications.

Ginkgo Bioworks

Grant in 2023
Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Naobios

Grant in 2023
Naobios is a contract development and manufacturing organization (CDMO) located in Saint Herblain, France. The company specializes in bioprocess development and offers good manufacturing practice (GMP) production services for clinical batches of various biological products, including viral vaccines, oncolytic viruses, viral vectors, and challenge agents. With expertise in optimizing production processes, Naobios supports the development of live vaccine products, contributing to advancements in biopharmaceutical manufacturing.

Vitrivax

Grant in 2023
VitriVax is a biotechnology startup based in Boulder, Colorado, dedicated to advancing vaccine formulation through its innovative technology platform. The company has developed proprietary atomic layering thermostable antigen and adjuvant (ALTA) technology, which aims to enhance the effectiveness, affordability, and accessibility of both human and animal vaccines worldwide. This technology allows for the creation of thermostable, single-shot vaccines that can maintain or improve immune responses, enabling the incorporation of prime and booster doses in a single administration. With significant financial backing from various organizations, including the Bill and Melinda Gates Foundation, VitriVax addresses critical barriers to global vaccination, striving to improve public health outcomes.

LTS Lohmann Therapie-Systeme AG

Grant in 2023
LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Kyron Learning

Grant in 2023
Kyron Learning is an educational technology company that aims to provide equitable access to one-on-one education. It develops a platform to accelerate the creation of interactive courses, featuring AI-driven course generation tools, customizable content, and actionable learner insights to help educators design engaging and efficient learning experiences with minimal effort.

Micron Biomedical

Grant in 2023
Founded in 2014, Micron Biomedical is a clinical-stage biopharmaceutical company based in Atlanta, Georgia. It specializes in developing microneedle patches for vaccines, aiming to enhance protective effects and patient compliance while simplifying administration.

Osmo

Grant in 2023
Osmo is a technology company that equips computers with the ability to sense smell using advanced AI and olfactory science. Initially focused on enhancing fragrance products, Osmo's long-term goal is to improve human health and well-being through innovative applications of smell detection.

Philips

Grant in 2023
Philips is a global technology company focused on health technology and improving people’s health and well-being through meaningful innovation. It offers a broad portfolio spanning diagnostic imaging, ultrasound, image-guided therapy, patient monitoring, health informatics, and consumer health products, as well as home care devices. The company operates across three segments—diagnosis and treatment, connected care, and personal health—and also develops lighting and consumer electronics for everyday use. Philips serves hospitals, clinics, and homes, applying advanced technologies to support prevention, diagnosis, treatment, and home-based care while pursuing sustainable, user-centered solutions.

BiomEdit

Grant in 2023
BiomEdit discovers, designs, and develops novel probiotics and microbiome-derived bioactives using a unique platform that combines high-throughput sequencing and data analytics. Their products aim to promote animal health without antibiotics, addressing unmet needs in animal agriculture and food security.

Axmed

Grant in 2023
Axmed is a business focuses on LMICs and strengthens the purchasing power of these markets to ensure the supply of cost-effective, high-quality medicines. We partner exclusively with authorized, high-quality pharmaceutical companies and certified caregivers to accelerate access to medicines.

CanSinoBIO

Grant in 2023
CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

Salient

Grant in 2023
Salient creates a weather intelligence platform that combines novel ocean and land-surface data with machine learning and climate expertise to provide accurate subseasonal-to-seasonal (S2S) weather forecasts 2 to 52 weeks ahead. Salient's tools sift through large datasets to identify complex climate system relationships in order to provide accurate forecasts used in agriculture, energy, finance, supply chain, and other industries. Salient utilizes scientific knowledge to assist individuals and organizations in better understanding and preparing for the increasing volatility of climate change.

STRM.BIO

Grant in 2023
STRM.BIO is a biotechnology company focused on advancing gene therapy through the innovative use of extracellular vesicles (EVs). By leveraging the natural properties of EVs, which can efficiently deliver nucleic acids and proteins, the company aims to establish a new class of therapeutics that enhance the effectiveness of existing treatments while simplifying the delivery process. STRM.BIO emphasizes safety and practicality in its approach, utilizing EVs as low-immunogenic carriers that can be mass-produced for commercial use. The company's mission is to fulfill the potential of gene therapy by providing patients with more effective and accessible treatment options.

Scentian Bio

Grant in 2023
Scentian Bio is a biotechnology company that develops innovative biosensor devices by integrating insect biology with nanotechnology. These devices leverage insect odorant receptors to create advanced sensing solutions tailored for applications in the medical and food industries. Scentian Bio's technology employs machine learning to detect volatile organic compounds, enabling the identification of off-notes in food and beverages, as well as the detection of fraud and adulteration in raw materials. By providing access to this sophisticated sensor technology, Scentian Bio aims to translate nature's sensory capabilities into practical applications for various commercial uses.

AN2 Therapeutics

Grant in 2023
AN2 Therapeutics is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative medicines targeting infectious diseases. Established in 2017, the company focuses on advancing a clinical-stage antibacterial compound and has a strategic partnership with Brii Biosciences.

GE Healthcare

Grant in 2023
GE Healthcare specializes in medical technology, offering a wide range of products including medical imaging systems, information technologies, diagnostics, patient monitoring devices, and biopharmaceutical manufacturing solutions. With a global presence, they aim to enhance patient care and outcomes through innovative healthcare solutions.

Anheuser-Busch InBev

Post in 2023
Anheuser-Busch InBev is the world's largest brewer and a leading player in the consumer goods sector. Established through the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch, the company boasts a diverse portfolio that includes six of the top ten beer brands by volume. It distributes a total of 23 brands that generate over $1 billion in retail sales. In addition to its brewing operations, Anheuser-Busch InBev manufactures and distributes both alcoholic and non-alcoholic beverages. The company has also developed a proprietary business-to-business platform, BEES, which digitizes the retail experience by connecting various steps in the distribution process to enhance consumer access. Anheuser-Busch InBev's strategic acquisitions, including the purchase of SABMiller in 2016, have further solidified its position in the global market.

Fulbright University Vietnam

Grant in 2023
Fulbright University Vietnam, based in Ho Chi Minh City, is a higher education institution that aims to bridge the gap between Vietnam's educational priorities and the demands of its job market. It offers interdisciplinary undergraduate and graduate programs in liberal arts, sciences, and engineering, focusing on developing students' practical skills and critical thinking. The university is committed to fostering diversity and accessibility through financial aid and scholarship opportunities. Its assets are managed by an executive management team.

Nuoc.Solutions

Grant in 2023
Nuoc.Solutions aims to create and foster innovative, sustainable, and efficient solutions to pressing water problems in Vietnam.

American University of Beirut

Grant in 2023
The American University of Beirut (AUB) is a prominent educational institution established in 1866, originally known as Syrian Protestant College until its name change in 1920. Located in Beirut, Lebanon, AUB follows the American liberal arts model and offers a comprehensive range of programs, including bachelor's, master's, M.D., and Ph.D. degrees across six faculties: Agricultural and Food Sciences, Arts and Sciences, Engineering and Architecture, Health Sciences, Medicine, and Business. The university promotes a teaching-centered research environment and emphasizes critical thinking, personal integrity, and civic responsibility among its approximately 8,000 students. With a faculty of around 800, AUB maintains a student-faculty ratio of 11.2 to 1. The institution is accredited by the Commission on Higher Education of the Middle States Association of Colleges and Schools in the United States and has been coeducational since 1922, with a balanced student demographic of 50 percent male and 50 percent female. The primary language of instruction is English, except for courses offered in the Arabic Department and other language programs.

Lahore University of Management Sciences

Grant in 2023
The Lahore University of Management Sciences (LUMS) is a national university, established by sponsors belonging to the country’s leading private and public sector corporations. The goal of the sponsors is to develop an institution, which would provide rigorous academic and intellectual training and a viable alternative to education comparable to leading universities across the world.

EHA Clinics

Grant in 2023
EHA Clinics delivers quality health care that is accessible, effective, and affordable. The company leverages technology and a skilled team to provide a superior experience, better outcomes, and lower costs for individuals, families, and businesses. Members gain seamless access to a comprehensive network that integrates routine medical care, laboratory services, pharmacies, optometry, dental care, urgent care, and specialist care. Services are available 24/7 through convenient locations, telehealth virtual visits, and home care, ensuring continuous and convenient care.

Bactolife

Series A in 2023
Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

A-Alpha Bio

Grant in 2023
A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Aptitude Medical Systems

Grant in 2023
Aptitude Medical Systems is a biotechnology research company specializing in molecular recognition technology that utilizes aptamers to address the limitations of traditional antibodies. By developing highly stable and resistant aptamers, the company offers solutions that bind with high affinity and specificity to challenging targets, even discriminating between targets that differ by a single functional group. This innovation enables a range of applications across life sciences, diagnostics, and therapeutics, facilitating the creation of advanced products tailored to meet the stringent demands of molecular recognition. Through its partnerships, Aptitude aims to advance the capabilities of molecular diagnostics and therapeutic interventions.

CO-DIAGNOSTICS

Grant in 2023
Co-Diagnostics, Inc. is a molecular diagnostics company based in Salt Lake City, Utah, founded in 2013. The company specializes in the development, manufacture, and marketing of advanced diagnostic technologies that focus on the detection and analysis of nucleic acid molecules, such as DNA and RNA. In addition to creating reagents for diagnostic tests, Co-Diagnostics offers self-contained lab systems that incorporate diagnostic equipment from other manufacturers. The company also leverages its proprietary technology to design targeted tests for identifying genetic markers, which can be utilized in various industries beyond infectious diseases, while licensing these tests to specific customers.

SoapBox Labs

Grant in 2023
SoapBox Labs Ltd., established in 2013 and based in Dublin, Ireland, specializes in developing automated speech recognition solutions tailored to children's voices. The company offers a range of products, including reading and language learning tools, as well as gaming solutions that incorporate voice control, AR, VR, and IoT. Their technology, which is COPPA and GDPR compliant, is integrated into various applications such as toys, robotics, and educational platforms, catering to multiple languages and providing accurate, age-appropriate, and safe voice-enabled experiences for children.

Aphea.Bio

Series C in 2023
Aphea.Bio is a company focused on developing next-generation biopesticides and biostimulants derived from natural microorganisms. Its biopesticides serve as an alternative to conventional chemical pesticides, addressing the increasing pressure on synthetic chemical use in agriculture. Additionally, the company creates biostimulants that enhance crop growth by improving the uptake of nutrients from the soil. Aphea.Bio's products aim to sustainably increase crop yields and health, specifically targeting crops such as maize and wheat. By utilizing proprietary technologies, the company accelerates the discovery of innovative biocontrol and biostimulant solutions, enabling farmers to manage pests, diseases, and fertilizer application more effectively.

Myna Mahila Foundation

Grant in 2023
Myna Mahila Foundation is a non-governmental organization that provides employment and skills to women in slum neighborhoods.

Latham BioPharm Group

Grant in 2023
Latham BioPharm Group provides insight, knowledge, and a network to unite teams and technologies in the life sciences. It offers consulting across vaccine, therapeutic, medical device, and diagnostic product development, including business development, program management, CMC, quality, regulatory, and strategic guidance. The team averages more than 20 years of experience and includes former executives at startups and Fortune 200 companies, with some having government experience. Over more than two decades, the firm has helped clients identify, evaluate, fund, manage, and monetize opportunities in diverse segments, generating government funding and licensing investments. Its services cover strategy and portfolio analysis, market research, and commercial and government asset analysis to inform decisions and connect with target markets. It also assists in securing funding through business development and non-dilutive funding services and moves programs toward value inflection points via program management and product development teams.

Lectrolyst

Grant in 2023
Lectrolyst is a technology company that specializes in developing electrochemical solutions for chemical production. They use electricity to convert waste CO2 and renewable feedstocks into fine chemical components, offering scalable, on-site solutions tailored to industrial clients' needs. This process aims to reduce carbon emissions and promote more sustainable chemical production, helping clients minimize their environmental impact and reliance on fossil fuels.

Aegis Life

Grant in 2023
Aegis Life is a biotechnology company specializing in nucleic acid delivery technology, Fusogenix PLV. With over two decades of research, they focus on accelerating the discovery, clinical development, and manufacture of vaccines and therapeutics for infectious diseases.

Council for Scientific and Industrial Research

Grant in 2023
The Council for Scientific and Industrial Research, commonly known as the CSIR, is a world-class African research and development organisation established through an Act of Parliament in 1945. The CSIR undertakes directed, multidisciplinary research and technological innovation that contributes to the improved quality of life of South Africans. The organisation plays a key role in supporting government’s programmes through directed research that is aligned with the country’s priorities, the organisation’s mandate and its science, engineering and technology competences. Key issues that the CSIR seeks to address through various interventions include: creating a vibrant economy and employment opportunities; building a capable state that is able to consistently deliver high-quality services for all South Africans; contributing to the development of economic and social infrastructure like transport, energy, water resources and ICT networks. The CSIR’s shareholder is the South African Parliament, held in proxy by the Minister of Science and Technology.

Hyperfine

Grant in 2023
Hyperfine is a pioneering medical device company that developed Swoop®, the world's first FDA-cleared point-of-care MRI system. Designed to enhance patient access to critical care, Swoop produces high-quality images rapidly and at a lower cost than conventional MRIs, enabling clinicians to diagnose and treat patients swiftly in various clinical settings.

Medicines for All Institute

Grant in 2023
The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.